Home・Listă Acțiuni・Zentalis Pharmaceuticals Inc

Zentalis Pharmaceuticals Inc

Închisă

4.08 8.22

Cumpără Vinde

Rezumat

Modificarea prețului

24h

Curent

Minim

3.71

Maxim

4.11

Indicatori cheie
By Trading Economics
Venit	-42M -78M
EPS	-0.59
Angajați	106
EBITDA	-42M -77M

Recomandări
By TipRanks
Recomandări	Puternic Cumpărare
Prognoză pe 12 luni	+114.84% upside

Dividende
By Acuity
Următoarele câștiguri	6 nov. 2026

Statistici piață
By TradingEconomics
Capitalizare de piață	25M 356M
Deschiderea anterioară	-4.14
Închiderea anterioară	4.08

Zentalis Pharmaceuticals Inc Grafic

Performanțele din trecut nu reprezintă un indicator fiabil al rezultatelor viitoare.

Știri relevante

3 sept. 2026, 23:56 UTC

C.H. Robinson Worldwide shares are lower in after-market trading, despite a broader market rally amid reduced interest rate hike expectations.

3 sept. 2026, 23:56 UTC

News

Missouri American Water acquired Neosho's water systems for $34.5 million, adding 5,400 customers. Shares of American Water Works traded higher in after-market hours.

3 sept. 2026, 23:56 UTC

SiTime Corp shares are lower in after-market hours, continuing a decline that began earlier, despite gains in major indices.

3 sept. 2026, 23:56 UTC

Elme Communities shares traded roughly flat in after-market hours. Broader market trends reflect gains in major averages amid reduced interest rate hike expectations.

3 sept. 2026, 23:56 UTC

News

Correlated Moves

Paychex receives a buy rating on strong revenue growth and strategic AI integration. After-market trading has shown little change since Thursday's close.

3 sept. 2026, 23:56 UTC

News

Jefferies initiated coverage on Nexgen Energy with a Buy rating and a C$21 price target. Shares moved higher in after-market hours.

3 sept. 2026, 23:56 UTC

Tapestry Inc. shares rose slightly in after-market trading, reflecting broader market gains amid reduced interest rate hike expectations. They remain below their 20-day moving average.

3 sept. 2026, 23:56 UTC

Loews Corp shares are higher in after-market hours, reflecting broader market gains amid reduced interest rate hike expectations.

3 sept. 2026, 23:56 UTC

Union Pacific Corp shares are higher in after-market trading, following gains in major indices amid reduced interest rate hike expectations, according to CME Group's FedWatch Tool.

3 sept. 2026, 23:56 UTC

Sportsman's Warehouse shares advanced in after-market trading, reflecting broader market gains amid reduced expectations for an interest rate hike.

3 sept. 2026, 23:56 UTC

CRISPR Therapeutics AG shares are lower in after-hours trading, continuing a decline since Thursday's close, despite broader market gains. No specific news was identified.

3 sept. 2026, 23:56 UTC

General Motors traded roughly flat after-market hours amid strong market momentum driven by reduced interest rate hike expectations, according to CME Group's FedWatch Tool.

3 sept. 2026, 23:56 UTC

Wingstop Inc shares are trading higher in after-market hours, supported by strong gains in major indices amid reduced interest rate hike expectations, according to CME Group.

3 sept. 2026, 23:51 UTC

Exelon Corp shares are lower in after-market hours, diverging from broader market gains amid anticipation of upcoming employment data. No specific news was identified.

3 sept. 2026, 23:51 UTC

Japan's Household Spending Falls 3.6% YoY in July, Marking Eighth Straight Month of Decline Amid Economic Uncertainty

3 sept. 2026, 23:51 UTC

Japan's Household Spending MoM for July rises 0.5%, falling short of 2.6% expectations, raising concerns over consumer behavior amid a year-on-year decline of 3.6%.

3 sept. 2026, 23:51 UTC

Canada's Ivey PMI forecasted to rise to 56.2 in August, signaling cautious optimism amid mixed business confidence trends and regional recovery signals.

3 sept. 2026, 23:51 UTC

Iovance Biotherapeutics Inc shares are higher in after-market trading, maintaining a position above its 20-day moving average amid broader market gains.

3 sept. 2026, 23:51 UTC

News

Regeneron Pharmaceuticals faces a class action lawsuit over misleading statements about its Phase III Fianlimab-Libtayo Study, with shares trading lower in after-market hours.

3 sept. 2026, 23:51 UTC

News

Social Media

Dutch Bros Inc filed a mixed securities shelf registration, enabling potential issuance of various securities. Shares are trading higher in after-market hours.

3 sept. 2026, 23:51 UTC

Yelp Inc shares are higher in after-market trading, following gains in the broader market. No specific company news was identified to explain the movement.

3 sept. 2026, 23:51 UTC

News

Social Media

Tesla Inc. shares are lower in after-market trading following the invite-only launch event for its Cybercab in Austin, as details remain restricted.

3 sept. 2026, 23:51 UTC

Shake Shack Inc shares are lower in after-market hours, continuing a downward trend below the 20-day moving average and nearing the one-month range low.

3 sept. 2026, 23:46 UTC

Hilton Worldwide Holdings Inc shares are trading higher in after-market hours, supported by gains in major indices amid anticipation of Friday's employment report.

3 sept. 2026, 23:46 UTC

Correlated Moves

Kimco Realty Corp shares are lower in after-market hours, reflecting a decline since Thursday's close. Broader market trends also show weakness.

3 sept. 2026, 23:46 UTC

News

Weyerhaeuser Co remains about 4.95% below its 20-day moving average. Shares were roughly flat in after-market hours following a price target cut to $28.

3 sept. 2026, 23:46 UTC

FedEx Corp shares are lower in after-market trading, reflecting a decline from Thursday's close. The stock showed initial strength before pulling back.

3 sept. 2026, 23:46 UTC

Correlated Moves

AMETEK Inc. shares declined in after-market trading, reflecting broader small-cap market trends amid significant gains in major indices earlier in the session.

3 sept. 2026, 23:46 UTC

Correlated Moves

Box Inc shares are lower in after-market hours following significant volatility. The decline may be linked to a drop in Asana Inc's stock.

3 sept. 2026, 23:46 UTC

Marcus & Millichap shares are lower in after-market trading, despite broader market gains. No specific news was identified to explain the decline.

Comparație

Modificare preț

Zentalis Pharmaceuticals Inc Așteptări

Obiectiv de preț

By TipRanks

114.84% sus

Prognoză pe 12 luni

Medie 8.83 USD 114.84%

Maxim 11 USD

Minim 5 USD

În baza a 6 analiști de pe Wall Street care oferă obiective de preț pe 12 luni pentruZentalis Pharmaceuticals Inc - Dist în ultimele 3 luni.

Consens privind evaluarea

By TipRanks

Puternic Cumpărare

6 ratings

Cumpărare

Păstrare

Vânzare

Ținând cont de 6 analiști care au acordat evaluări ale acțiunilor Zentalis Pharmaceuticals Inc - Dist în ultimele 3 luni.

Date financiare

Cheltuieli de vânzare și administrare

Cheltuieli de exploatare

Profit pre-impozitare

Vânzări

Costul vânzărilor

Profit brut din vânzări

Cheltuieli cu dobânzile pe datorie

EBITDA

Profit operațional

Despre Zentalis Pharmaceuticals Inc

Zentalis Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on discovering and developing small molecule therapeutics for the treatment of various cancers. Its products candidatures include the ZN-c3, an inhibitor of WEE1, a protein tyrosine kinase for the treatment of inhibitor for advanced solid tumors and hematological malignancies; in Phase 2 clinical trial as a monotherapy for the treatment of uterine serous carcinoma indications; Phase 2 clinical trial in Cyclin E1 driven high-grade serous ovarian cancer, fallopian tube, or primary peritoneal cancer; Phase 1/2 clinical trial in combination with PARPi for platinum-resistant ovarian cancer; Phase 1b clinical trial in combination with chemotherapy in platinum-resistant ovarian, and peritoneal or fallopian tube cancer; Phase 1/2 clinical trial in combination with chemotherapy in relapsed or refractory osteosarcoma; Phase 1/2 clinical trial with encorafenib and cetuximab for mutant metastatic colorectal cancer; and Phase 1/2 clinical trial in combination with chemotherapy in pancreatic cancer. The company's products pipeline also includes ZN-d5, an oral small molecule inhibitor of B-cell lymphoma 2, for hematological malignancies and related disorders; and BCL-xL heterobifunctional degrader, a member of the anti-apoptotic BCL-2 proteins, for solid tumors and hematological malignancies. Zentalis Pharmaceuticals, Inc. has licensing agreements and strategic collaborations with Recurium IP Holdings, LLC; Pfizer, Inc.; Zentera Therapeutics; Dana-Farber; and GlaxoSmithKline plc. The company was incorporated in 2014 and is headquartered in New York, New York.